Abstract
GlaxoSmithKline has partnered with Exscientia to use artificial intelligence to develop small molecules against up to 10 drug targets. Exscientia seeks to use AI to design molecules with a desired balance of potency, selectivity, and pharmacokinetics. GSK will provide the firm with research funding and up to $42 million in milestone payments as molecules reach preclinical studies. In May, Exscientia joined with Sanofi to develop bispecific small molecules against metabolic diseases targets.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
